Beacon Pharmaceuticals PLC

DSE:BEACONPHAR Stock Report

Market Cap: ৳31.4b

Beacon Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Beacon Pharmaceuticals has been growing earnings at an average annual rate of 9.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 14.1% per year. Beacon Pharmaceuticals's return on equity is 7.9%, and it has net margins of 4.6%.

Key information

9.3%

Earnings growth rate

9.3%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate14.1%
Return on equity7.9%
Net Margin4.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Beacon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DSE:BEACONPHAR Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,1845123,9020
30 Jun 2410,7025213,6720
31 Mar 249,8934663,6430
31 Dec 239,4026623,4270
30 Sep 238,8126513,1990
30 Jun 238,5105103,2950
31 Mar 238,1906992,6690
31 Dec 227,8879362,4270
30 Sep 227,7748122,5290
30 Jun 228,0239352,4990
31 Mar 226,9769362,2800
31 Dec 217,7331,1702,3160
30 Sep 217,8391,1582,3470
30 Jun 217,1218632,3070
31 Mar 217,7191,0072,7480
31 Dec 206,4936032,6690
30 Sep 205,7973962,6180
30 Jun 205,5913812,5330
31 Mar 205,3681152,2540
31 Dec 195,1551042,1840
30 Sep 194,9191212,0570
30 Jun 194,6471181,9590
31 Mar 194,5641761,8850
31 Dec 184,2811621,7170
30 Sep 183,9171421,5730
30 Jun 183,7611261,5660
31 Mar 183,2951221,3760
31 Dec 173,2591181,3780
30 Sep 173,0821141,3010
30 Jun 172,9481041,2000
31 Mar 173,004891,1680
31 Dec 162,764671,0820
30 Sep 162,640631,0300
30 Jun 162,492619370
31 Mar 162,279588170
31 Dec 152,169587600
30 Sep 152,128437320
30 Jun 152,053397080
31 Mar 152,085327280
31 Dec 141,970276620
30 Sep 141,898256240
30 Jun 141,690245550
31 Mar 141,502115270
31 Dec 131,482125460

Quality Earnings: BEACONPHAR has high quality earnings.

Growing Profit Margin: BEACONPHAR's current net profit margins (4.6%) are lower than last year (7.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BEACONPHAR's earnings have grown by 9.3% per year over the past 5 years.

Accelerating Growth: BEACONPHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BEACONPHAR had negative earnings growth (-21.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.3%).

Return on Equity

High ROE: BEACONPHAR's Return on Equity (7.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 02:30
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beacon Pharmaceuticals PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution